B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

HIPK1

MOLECULAR TARGET

homeodomain interacting protein kinase 1

UniProt: Q86Z02NCBI Gene: 20485124 compounds

HIPK1 (homeodomain interacting protein kinase 1) is targeted by 24 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting HIPK1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1alvocidib4.5291
2foretinib4.3476
3ruxolitinib4.2368
4pi 1034.1764
5bosutinib4.0858
6bi 25364.0154
7nintedanib3.6136
8bms 3870323.4731
9tae 6843.4330
10fedratinib3.4029
11bisindolylmaleimide ix3.1422
12dovitinib3.0921
13lestaurtinib3.0420
14ruboxistaurin2.9418
15r 4062.8316
16pha 6657522.7114
17plx 47202.7114
18kw 24492.6413
19gsk 6906932.6413
20ast 4872.5612
21su 0148132.208
22enzastaurin2.087
23Sorafenib1.393
24pictilisib0.691

About HIPK1 as a Drug Target

HIPK1 (homeodomain interacting protein kinase 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 24 compounds with documented HIPK1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

HIPK1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.